Clinical trial

Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo

NCT00282178

Study summary

ClinicalTrials.gov

Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Hydrochlorothiazide Normalized identity: hydrochlorothiazide View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Candesartan Normalized identity: candesartan View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-04-01

PhasePHASE2

Conditions

Hypertensionunresolved

Obesityverified · MONDO: obesity disorder

Interventions

HydrochlorothiazideDRUG · verified · RxNorm: hydrochlorothiazide

PlaceboDRUG

CandesartanDRUG · verified · RxNorm: candesartan

Sponsors & collaborators

Umeå Universitylead sponsor

Sahlgrenska University Hospitalcollaborator

AstraZenecacollaborator

Mapped research locations

UmeåSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00282178 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.